Nordic ListingsIssuer Report
Promimic AB: Quarterly Trading Report 2025 Q3
Promimic AB: Quarterly Trading Report 2025 Q3https://view.news.eu.nasdaq.com/view?id=be77d8c0fe6db21aec1ec851d19816308&lang=en&src=omxlink
Promimic AB: Quarterly Trading Report 2025 Q3
Earlier from Promimic Ab
- PRO: Record new agreements, positive EBITDA, and updated growth targets despite market headwinds
- PRO: Q1 2025 saw sales growth, new strategic deals, and improved cash flow despite a net loss
- PRO: Record sales and clinical milestones achieved, with robust growth outlook for 2025
- PRO: Sales up 6% in Q3, with record product approvals and strong royalty growth